Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Amino acid sequence disclosed in whole or in part; or...
Reexamination Certificate
2005-06-21
2005-06-21
Winkler, Ulrike (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Amino acid sequence disclosed in whole or in part; or...
C424S192100, C424S204100, C424S207100, C424S208100, C435S007100, C435S069700, C530S300000, C530S350000, C536S023400, C536S023720
Reexamination Certificate
active
06908612
ABSTRACT:
The invention relates to chimeric molecules comprising a virus coat sequence and a receptor sequence that can inter-act with each other to form a complex that is capable of binding a co-receptor. Such chimeric molecules therefore exhibit functional properties characteristic of a receptor-coat protein complex and are useful as agents that inhibit virus infection of cells due to occupancy of a co-receptor present on the cell. In particular aspects, the chimeric polypeptide includes an immunodeficiency virus envelope polypeptide, such as that of HIV, SIV, FIV, FeLV, FPV and herpes virus. Receptor sequences suitable for use in a chimeric polypeptide include, for example, CD4 D1D2 and CD4M9 sequences.
REFERENCES:
patent: 5420030 (1995-05-01), Reitz, Jr. et al.
patent: 5518723 (1996-05-01), DeVico et al.
patent: 5576000 (1996-11-01), Reitz, Jr. et al.
patent: 5689313 (1997-11-01), Sotheran
patent: 5770572 (1998-06-01), Gershoni
patent: 5843454 (1998-12-01), Devico et al.
patent: 5871913 (1999-02-01), Maddon et al.
patent: 5925741 (1999-07-01), Gershoni
patent: 6020468 (2000-02-01), Gershoni
patent: 6060316 (2000-05-01), Young et al.
patent: 6143876 (2000-11-01), Gershoni
patent: 6165722 (2000-12-01), Gershoni et al.
patent: 6329202 (2001-12-01), Gershoni
Freed et al. Mutational analysis of the cleavage sequence of the human immunodeficiency virus type 1 envelope glycoprotein precursor gp160. Journal of Virology (1989) vol. 63, No. 11, pp. 4670-4675.
Stratagene Catalog, Affinity protein expression and purification system,(1997/1998) p. 112.
Fouts et al. Expression and characterization of a single-chain polypeptide analogue of the human immunodeficiency virus type 1 gp120-CD4receptor complex. Journal of Virology. Dec. 2000, vol. 74, No. 24, pp. 11427-11436.
Gershoni, et al. HIV binding to its receptor creates specific epitopes for the CD4/lgp120 complex. FASEB Journal. Sep. 1993, vol. 7, pp. 1185-1187. See.
Claudio Vita. “Rational engineering of a miniprotein that reproduces the core of the CD4 site interacting with HIV-1 envelope glycoprotein.” PNAS, Nov. 9, 1999, vol. 96, No. 23, patent. 13091-13096.
R.A. Kaup et al., “Shutting down HIV,”, Nature, 370; 416 (1994).
R.A. Kaup et al., “Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome,” Journal of Virol, 68; 4650-4655 (1994).
E.A. Emini, et al., “Prevention of HIB-1 infection in chimpanzees by gp120 V3 domain-specific monoclonal antibody,” Nature, 355; 728-739 (1992).
R. Shibata et al., “Neutralizing antibody directed against the HIV-1 envelope glycoprotein can completely block HIV-1/SIV chimeric virus infections of macaque monkeys,” Nature Medicine, 5; 204-210 (1999).
M.C. Gauduin et al., “Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1,” Nature Medicine, 3; 1389-1393 (1997).
P.W. Parren et al., “Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site,” AIDS, 9; F1-F6 (1995).
J.W. Eichberg et al., “Prevention of HIV infection by passive immunization with HIVIG or CD4-IgG,” AIDS Res. Hum. Retroviruses, 8; 1515 (1992).
R.H. Ward et al, “Prevention of HIV-1 IIIB infection in chimpanzees by CD4 immunoadhesin,” Nature, 352; 434-436 (1991).
J.L. Heeney et al., “Beta-chemokines and neutralizing antibody titers correlate with sterilizing immunity generated in HIV-1 vaccinated macaques,” Proc. Nat. Acad. Sci. U.S.A., 95; 10803-10808 (1998).
Mascola et al., “Protection of macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies,” Jour. Of Virol., 73; 4009-4018 (1999).
J.P. Moore et al., “HIV-1 neutralization: the consequences of viral adaptation to growth on transformed T cells,” AIDS, 9; S117-S136 (1995).
Q.J. Sattentau, “Neutralization of HIV01 by antibody,” Curr. Opin. Immun., 8; 540-545 (1996).
R. Wyatt et al., “The HIV-1 envelope glycoproteins: fusogens, antigens, and immunogens,” Science, 280; 1884-1888 (1998).
Devico Anthony Louis
Fouts Timothy R.
Tuskan Robert G.
Fuierer Marianne
Hultquist Steven J.
University of Maryland Biotechnology Institute
Winkler Ulrike
Yang Yongzhi
LandOfFree
Virus coat protein/receptor chimeras and methods of use does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Virus coat protein/receptor chimeras and methods of use, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Virus coat protein/receptor chimeras and methods of use will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3519452